Lessons on inpatient hyperkalemia from the 2017 hospital meeting

The plenary halls at Mandalay Bay in May 2017 framed hyperkalemia as more than an electrolyte blip; presenters argued it was a marker of complex comorbidity that demanded structured, multidisciplinary response. Hospitalists left Las Vegas with sharper triage pathways, refreshed ECG triggers, and renewed attention to renin-angiotensin-aldosterone blocker management. Across workshops and poster walks, the message was consistent: an inpatient spike in serum potassium is rarely an isolated event and almost always tests the seam between emergency, renal, and cardiology teams.

For clinicians practising in Australia, these international takeaways sit alongside local realities such as PBS listings of newer binders, TGA-approved agents available under specific criteria, and habitual use of potassium-based salt substitutes on barbecues and home kitchens. This article walks through what the 2017 proceedings added, where Australian practice already aligned, and which ward-level decisions are now dated, drawing on materials circulated through the official conference portal.

Recognising the dangerous pattern early

Las Vegas presentations repeatedly grouped inpatient hyperkalemia around three triggers: a recent dose change in an ACE inhibitor or ARB, an acute kidney insult from contrast or sepsis, and oral potassium supplementation including salt substitutes. Australian pharmacists have long flagged that lite salt products containing potassium chloride are popular in suburban kitchens from Brisbane to Adelaide, which can complicate the home picture once a patient is readmitted.

The 2017 content also stressed pre-emptive ECG for any potassium above 6.0 mmol/L, or above 5.5 mmol/L with suggestive symptoms such as muscle weakness or paresthesia. Peaked T waves, widened QRS, and loss of P waves were described as decision points, not observations. Audiences were reminded that dialysed patients and those on MRAs present differently, and that reliance on a single lab value without an ECG frame is a recurring root cause of delayed escalation.

Stabilising the membrane before chasing numbers

A recurring theme was that calcium gluconate 10% buys time, not numbers. The 2017 faculty urged hospitalists to give 10 mL of 10% calcium gluconate over 2–3 minutes when ECG changes are visible, repeating once if needed while arranging definitive therapy. This framing matters on Australian medical assessment units where junior staff often ask whether calcium lowers potassium; the correct mental model is protection of the myocardial threshold.

The faculty also pointed out that calcium is safe in most patients, including those on dialysis, and that withholding it while waiting for repeat bloods is a recognised source of preventable arrhythmia. Several Las Vegas case discussions showed that normalisation of the ECG, not the lab, should determine the next dose, and that pacing wires were rarely needed when calcium was given promptly.

Shifting potassium into cells

Insulin with dextrose was reaffirmed as the workhorse intracellular shifter. The 2017 recommendations converged on 10 units of short-acting insulin with 25 g of dextrose, repeated glucose checks at 30 minutes, 60 minutes, and 4 hours, and a standing order for additional dextrose if BGL dropped below 7 mmol/L. Australian EDs in cities like Melbourne and Perth typically stock 50 mL ampoules of 50% dextrose, allowing a 25 g bolus to be drawn up easily and reducing preparation errors at the bedside.

Salbutamol nebuliser, while familiar to respiratory teams, was reframed as an adjunct rather than a standalone solution, with renewed caution in advanced CKD. Sodium bicarbonate retained a role when pH was below 7.2 and was not recommended as routine. Audiences were asked to document which therapies were given so that downstream teams could interpret rebound hyperkalemia predictably during handover.

Removing potassium from the body

The Las Vegas programme covered elimination options in detail. Loop diuretics were endorsed for volume-resuscitated patients with preserved urine output, while haemodialysis was strongly recommended for refractory cases, ECG instability, or end-stage kidney disease with K above 6.5 mmol/L. Sodium polystyrene sulfonate was reviewed critically, with several faculty arguing that its risk profile outweighed benefits for routine inpatient use in light of newer alternatives.

Two newer agents received attention: patiromer, a non-absorbed polymer that exchanges potassium for calcium in the colon, and sodium zirconium cyclosilicate, an inorganic crystal that traps potassium throughout the GI tract. Both showed rapid onset in trials, with full effect over days rather than minutes, positioning them as bridge or maintenance therapy rather than acute savers. Australian prescribers recognised that TGA registration had already occurred before the meeting, although funding pathways continued to mature under the PBS.

Continuing RAAS and MRA therapy when feasible

A second headline from the conference was the reluctance to stop RAAS blockade or MRAs indefinitely after one spike. Faculty presenters noted that withdrawing spironolactone in HFrEF simply because of a borderline reading was a documented contributor to readmission, and that pharmacy-led rechallenge protocols were increasingly common in North American centres. Cardio-renal outpatient clinics in Australia have paralleled this thinking since the PARADIGM-HF era.

The 2017 protocol template included a 48-hour binder overlap, a structured down-titration plan only if potassium persisted above 5.5 mmol/L twice, and a documented discussion with the patient's GP before formal cessation. Handback notes frequently referenced seasonal risks such as dehydration on outdoor work sites in regional Queensland or Western Australia, conditions that can flip borderline potassium into dangerous territory within a single shift.

Local access and the PBS dimension

For Australian audiences, the most practical translation of the 2017 talks is familiarity with local subsidy rules. The PBS schedule lists patiromer under specific authority criteria, generally for persistent hyperkalemia in patients where renin-angiotensin-aldosterone blockade is otherwise being withdrawn. Sodium zirconium cyclosilicate followed a similar trajectory. Hospital pharmacists in Sydney and Brisbane confirmed during the meeting that pharmacist-led titration protocols were reducing the need for inpatient loop diuretic escalation in eligible cardi-renal patients.

The economics matter because inpatient bed-days in Australia remain constrained, particularly during winter surges across the southern capitals. Presenters linked reduced length of stay to consistent binder use in the 48 to 72 hours after the acute shift, a finding that resonated with ward teams tracking four-hour access targets. Documentation of contraindicated salt substitutes, MRA cessation decisions, and sick-day plans were highlighted as part of the discharge bundle.

Ward systems and shared decision-making

Beyond pharmacology, the 2017 conference emphasised that hyperkalemia management is a hospital-system test. The Australian lens was sharpened by the compensation models review, which examined how after-hours coverage and quality incentives were being aligned with rapid response to electrolyte alerts.

Ward pharmacists running medication reconciliation within 24 hours of admission were cited as the single most effective intervention for catching hidden potassium loads, whether from cardiology-friendly salt substitutes, herbal preparations such as dried nettle, or unsupervised supplements. Shared decision-making conversations about MRA continuation, especially in patients with HFrEF and eGFR between 30 and 45, were framed as essential rather than optional. The 2017 consensus was clear: withdrawal of an evidence-based MRA simply because of a single borderline potassium is a missed opportunity if structured follow-up exists.

For Australian clinical teams rebuilding local protocols after the meeting, the practical next step is to pull a single month's worth of code blue and MET calls where hyperkalemia featured as a contributing or primary cause, then map those cases against the structured response outlined above to identify the single highest-yield change for the unit, whether that is nursing-initiated calcium administration under a standing order, pharmacist-led binder titration within 24 hours, or a default ECG within 30 minutes of any potassium above 5.5 mmol/L reported by the lab.